Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
The consequences of angiopoietin-like protein 3 (ANGPTL3) deficiency on postprandial lipid and lipoprotein metabolism has not been investigated in humans. We studied 7 homozygous (undetectable circulating ANGPTL3 levels) and 31 heterozygous (50% of circulating ANGPTL3 levels) subjects with familial combined hypolipidemia (FHBL2) due to inactivating ANGPTL3 mutations in comparison with 35 controls. All subjects were evaluated at fasting and during 6 h after a high fat meal. Postprandial lipid and lipoprotein changes were quantified by calculating the areas under the curve (AUCs) using the 6 h concentration data. Plasma changes of β-hydroxybutyric acid (β-HBA) were measured as marker of hepatic oxidation of fatty acids. Compared with controls, homozygotes showed lower incremental AUCs (iAUCs) of total TG (-69%, P < 0.001), TG-rich lipoproteins (-90%, P < 0.001), apoB-48 (-78%, P = 0.032), and larger absolute increase of FFA (128%, P < 00.1). Also, heterozygotes displayed attenuated postprandial lipemia, but the difference was significant only for the iAUC of apoB-48 (-28%; P < 0.05). During the postprandial period, homozygotes, but not heterozygotes, showed a lower increase of β-HBA. Our findings demonstrate that complete ANGPTL3 deficiency associates with highly reduced postprandial lipemia probably due to faster catabolism of intestinally derived lipoproteins, larger expansion of the postprandial FFA pool, and decreased influx of dietary-derived fatty acids into the liver. These results add information on mechanisms underlying hypolipidemia in FHBL2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ANGPTL3 is a genetically validated target for HTG to reduce ASCVD risk.11,77–79”
From Clinical review on triglycerides (2020) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Loss-of-function variants in ANGPTL3 have been associated with reduced plasma levels of TG, LDL-C, and HDL-C.32,64,65”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International physical activity questionnaire: 12-country reliability and validity
CRAIG, C. L., MARSHALL, A. L., SJ??STR??M, M., BAUMAN, A. E., BOOTH, M. L., AINSWORTH, B. E., PRATT, M., EKELUND, U., YNGVE, A., SALLIS, J. F., et al. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000078924.61453.fb · Cited by 21,619
Bioelectrical impedance analysis—part II: utilization in clinical practice
Kyle, U. G., Bosaeus, I., De Lorenzo, A. D., Deurenberg, P., Elia, M., Manuel Gómez, J., Lilienthal Heitmann, B., Kent-Smith, L., Melchior, J.-C., Pirlich, M., et al. (2004) · Clinical Nutrition · doi:10.1016/j.clnu.2004.09.012 · Cited by 2,350
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871 · cited 1×
“In observational studies, plasma concentrations of TGs in both fasting and fed state are associated with risk of coronary heart disease (1, 2).”
BackgroundSarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“In observational studies, plasma concentrations of TGs in both fasting and fed state are associated with risk of coronary heart disease (1, 2).”
BackgroundExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Lipoprotein lipase: from gene to obesity
Wang, H., & Eckel, R. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90920.2008 · Cited by 741
Sun, S. S., Chumlea, W. C., Heymsfield, S. B., Lukaski, H. C., Schoeller, D., Friedl, K., Kuczmarski, R. J., Flegal, K. M., Johnson, C. L., & Hubbard, V. S. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.2.331 · Cited by 692
Physiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 550
Indirect Calorimetry: A Practical Guide for Clinicians
Haugen, H. A., Chan, L., & Li, F. (2007) · Nutrition in Clinical Practice · doi:10.1177/0115426507022004377 · Cited by 512
Kersten, S., Mandard, S., Tan, N. S., Escher, P., Metzger, D., Chambon, P., Gonzalez, F. J., Desvergne, B., & Wahli, W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004029200 · Cited by 489
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“32,64,65 Which factors regulate the generation and clearance of chylomicron and very low-density lipoprotein remnants?”
BackgroundMetabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
“Angiopoietin-like proteins Three members of the angiopoietin-like (ANGPTL) family, ANGPTL3, ANGPTL4 and ANGPTL8, regulate peripheral TRL processing.”
BackgroundInfluentialClinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
ANGPTL3 deficiency and protection against coronary artery disease
Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467
“Studies in both mice and humans have demonstrated ANGPTL3 to be a potent inhibitor of LPL, particularly in the post-prandial state (41).”
BackgroundBeyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Funcke, J.-B., & Scherer, P. E. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r094060 · Cited by 327
Angiopoietin-like 3 in lipoprotein metabolism
Kersten, S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.119 · Cited by 220
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism.
Liu, H., & Peng, D. (2022) · PubMed Central · doi:10.1530/ec-21-0002 · Cited by 52
“Furthermore, ANGPTL3 deficiency could lead to declined postprandial lipid levels, possibly due to accelerated catabolic metabolism of TRLs and reduced flow of fatty acids into liver (116, 117).”
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
“107,108 Other members of the ANGPTL family are also involved in lipoprotein metabolism and insulin resistance.”
Self-citationEsan, O., & Wierzbicki, A. S. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 80
Cinkajzlová, A., Mráz, M., Lacinová, Z., Kloučková, J., Kaválková, P., Kratochvílová, H., Trachta, P., Křížová, J., Haluzíková, D., Škrha, J., et al. (2018) · Nutrition & Diabetes · doi:10.1038/s41387-018-0032-2 · Cited by 73
Morelli, M. B., Chavez, C., & Santulli, G. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1707806 · Cited by 67
“were also reported in subjects carrying the single-nucleotide polymorphism M259T, and in two individuals carrying the nonsense mutations S17X and E129X [47,101,105]; remarkably, these subjects exhibited extremely low plasma TGs and LDL-C levels and almost no detectable ANGPTL3 in their plasma [105].”
BackgroundThe Role of High-Density Lipoprotein Cholesterol in 2022
Sirtori, C. R., Corsini, A., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01012-y · Cited by 60
Costanzo, A. D., Leo, E. D., Noto, D., Cefalu, A. B., Minicocci, I., Polito, L., D’Erasmo, L., Cantisani, V., Spina, R., Tarugi, P., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.013 · Cited by 48
Self-citationNew insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases
Su, X., & Peng, D. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0659-y · Cited by 47
“Participants who received the therapy by 60 mg/week and presented a mean reduction in TG levels of 50%, in LDL-C levels of 33%, and in HDL-C levels of 27% [79].”
InfluentialAngiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
Tarugi, P., Bertolini, S., & Calandra, S. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.32.20170114 · Cited by 47
“[49] Minicocci I, Tikka A, Poggiogalle E, et al.”
BackgroundLipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 46
Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency
Arca, M., D’Erasmo, L., & Minicocci, I. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000668 · Cited by 43
“Differently, in a previous study in normal individuals there was no change in plasma levels of ANGPTL3 and ANGPTL4 during 6 h after a fat load [9].”
BackgroundResultSelf-citationOlkkonen, V. M., Sinisalo, J. P., & Jauhiainen, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.019 · Cited by 43
Self-citationMetabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State
Tikkanen, E., Minicocci, I., Hällfors, J., Costanzo, A. D., D’Erasmo, L., Poggiogalle, E., Donini, L. M., Würtz, P., Jauhiainen, M., Olkkonen, V. M., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312021 · Cited by 43
Self-citationThreshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins
Fazio, S., Minnier, J., Shapiro, M. D., Tsimikas, S., Tarugi, P., Averna, M. R., Arca, M., & Tavori, H. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-4043 · Cited by 40
Self-citationBini, S., D’Erasmo, L., Costanzo, A. D., Minicocci, I., Pecce, V., & Arca, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020742 · Cited by 41
Self-citationANGPTL3 Deficiency and Risk of Hepatic Steatosis
D’Erasmo, L., Martino, M. D., Neufeld, T., Fraum, T. J., Kang, C. J., Burks, K. H., Costanzo, A. D., Minicocci, I., Bini, S., Maranghi, M., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.065866 · Cited by 37
“…lipoprotein cholesterol, and VLDL. 4–6 FHBL2 is associated with increased lipoprotein lipase mass and activity in pos-theparin plasma, 7 and affected individuals have a marked reduction of postprandial lipemia, 8 along with lower plasma free fatty acids (FFA) and improved insulin sensitivity.”
BackgroundSelf-citationAnti-sense oligonucleotide therapies for the treatment of hyperlipidaemia
Wierzbicki, A. S., & Viljoen, A. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1196182 · Cited by 33
“well as highly reduced triglycerides, VLDL and HDL-C levels [60].”
BackgroundFoss‐Freitas, M. C., Akıncı, B., Neidert, A., Bartlett, V. J., Hurh, E., Karwatowska‐Prokopczuk, E., & Oral, E. A. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01589-4 · Cited by 32
“Treatment with vupanorsen also resulted in reduced levels in both, fasting and postprandial FFAs, consistent with previous reports on ANGPTL3 deficiency [16] and suggesting suppression of adipose tissue lipolysis.”
ResultD’Erasmo, L., Bini, S., & Arca, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00967-8 · Cited by 28
Self-citationBell, T. A., Liu, M., Donner, A. J., Lee, R. G., Mullick, A. E., & Crooke, R. M. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100101 · Cited by 21
“FHBL2 is a condition characterized by low levels of all the major lipoprotein classes (VLDL, LDL, and HDL) (9).”
BackgroundAngiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria
Gao, X., Suo, Y., Zhang, M., Wang, Y., Gao, X. Y., Bing, Q., & Liu, Q. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1052-1 · Cited by 21
Chen, M., Hsu, B., Lee, C., & Wang, J. (2020) · International Journal of Hypertension · doi:10.1155/2020/2980954 · Cited by 18
“Studies in mice and humans have shown that ANGPTL3 acts as a potent inhibitor of LPL, clearing TG-rich lipoproteins from circulation, particularly in the postprandial state [28].”
BackgroundTranscriptomic Therapy for Dyslipidemias Utilizing Nucleic Acids Targeted at ANGPTL3
Watts, G. F., Raal, F. J., & Chan, D. C. (2021) · Future Cardiology · doi:10.2217/fca-2021-0096 · Cited by 18
ANGPTL3 impacts proteinuria and hyperlipidemia in primary nephrotic syndrome
Zhong, F., Liu, S., Li, Y., Li, G., Liu, M., Wang, J., Cui, W., Suo, Y., & Gao, X. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01632-y · Cited by 18
“ANGPTL3 can significantly inhibit the activity of LPL, leading to reduced triglyceride and cholesterol decomposition and increased blood lipid levels, and is a key molecule that regulates lipid metabolism [7].”
BackgroundLevy, E. H., Beaulieu, J., & Spahis, S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.629222 · Cited by 18
Bini, S., Pecce, V., Costanzo, A. D., Polito, L., Ghadiri, A., Minicocci, I., Tambaro, F., Covino, S., Arca, M., & D’Erasmo, L. (2022) · Biomolecules · doi:10.3390/biom12040585 · Cited by 17
“However, it should be remembered that in conditions of a genetically determined absence of pharmacological inhibition of circulating ANGPTL3 by monoclonal antibodies, the level of FFAs is reduced in vivo [8,27].”
BackgroundResultSelf-citationRuhanen, H., Haridas, P. A. N., Minicocci, I., Taskinen, J., Palmas, F., Costanzo, A. D., D’Erasmo, L., Metso, J., Partanen, J., Dalli, J., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158679 · Cited by 18
“20 CETP and PLTP, since no significant differences in their activities were observed between homozygous ANGPTL3 LOF variant carriers and control subjects [27].”
BackgroundMethodSelf-citationHow ANGPTL3 Inhibition Will Help Our Clinical Practice?
Bini, S., Tramontano, D., Minicocci, I., Costanzo, A. D., Tambaro, F., D’Erasmo, L., & Arca, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01076-w · Cited by 15
Self-citationANGPTL3 serum concentration and rare genetic variants in Finnish population
Tikka, A., Metso, J., & Jauhiainen, M. (2017) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2017.1379608 · Cited by 14
“ANGPTL3 deficient subjects show a significantly blunted response in postprandial lipaemia [19] facilitated primarily via faster LPL-mediated catabolism of intestinally derived CM particles [17].”
BackgroundSelf-citationFlorentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 15
Fasting and Postload Nonesterified Fatty Acids and Glucose Dysregulation in Older Adults
Shitole, S. G., Biggs, M. L., Ix, J. H., Fretts, A. M., Tracy, R. P., Siscovick, D. S., Djoussé, L., Mukamal, K. J., & Kizer, J. R. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac044 · Cited by 11
“In addition, LPL in adipose endothelium is inhibited by angiopoietin-like 3, whose levels decrease postprandially, and by angiopoietin-like 4, whose levels are maximally expressed in the postabsorptive state (42).”
BackgroundEffect of complete, lifelong ANGPTL3 deficiency on triglyceride-rich lipoprotein kinetics
Fappi, A., Patterson, B. W., Burks, K. H., Davidson, N. O., Vaisar, T., Kanter, J. E., Bornfeldt, K., Fisher, E. A., Goldberg, I. J., Stitziel, N. O., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102152 · Cited by 10
Differential Effects of Bariatric Surgery on Plasma Levels of ANGPTL3 and ANGPTL4.
Bini, S., D’Erasmo, L., Astiarraga, B., Minicocci, I., Palumbo, M., Pecce, V., Polito, L., Costanzo, A. D., Haeusler, R. A., Arca, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.08.019 · Cited by 7
Self-citationShah, M., JAFFERY, M. F., ADAMS-HUET, B. A., Franklin, B., Oliver, J. M., & Mitchell, J. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172732 · Cited by 8
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 8
ANGPTL3 deficiency associates with the expansion of regulatory T cells with reduced lipid content
Grimaldos, A. P., Pacella, I., Bini, S., Tucci, G., Cammarata, I., Costanzo, A. D., Minicocci, I., D’Erasmo, L., Arca, M., & Piconese, S. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.09.014 · Cited by 7
Self-citationRecent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000348 · Cited by 6
Ossoli, A., Minicocci, I., Turri, M., Costanzo, A. D., D’Erasmo, L., Bini, S., Montavoci, L., Veglia, F., Calabresi, L., & Arca, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159263 · Cited by 4
Self-citationNew and Emerging Therapies for Dyslipidemia
Zambon, A., Averna, M. R., D’Erasmo, L., Arca, M., & Catapano, A. L. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.004 · Cited by 5
Self-citationInhibition of ANGPTL3 as a Target for Treating Dyslipidemias
Watts, G. F., Chan, D. C., & Raal, F. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00027-3 · Cited by 3
D’Erasmo, L., Tramontano, D., & Arca, M. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000941 · Cited by 3
Self-citationArca, M., Björnson, E., D’Erasmo, L., Costanzo, A. D., Bini, S., Minicocci, I., Tramontano, D., Covino, S., Ciarlo, G., Lombardi, M., et al. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70124 · Cited by 2
“1, Panels a and b) with concentrations barely rising above fasting levels (con-firming results reported earlier [13, 23]).”
InfluentialSelf-citationInvestigated treatments for lipoprotein lipase deficiency and related metabolic disorders
Lee, J.-H., & Hegele, R. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1311784 · Cited by 1
“triglycerides; further subjects with ANGPTL3 deficiency had a blunted response to post prandial lipemia compared to control subjects [108,109].”
BackgroundSíndrome de Quilomicronemia Familiar: Algoritmo Diagnóstico
Colaco, I. B., Araújo, F., Aguiar, P., Cruz, D., Bourbon, M., Duarte, J. S., & Veríssimo, M. T. (2021) · Medicina Interna · doi:10.24950/rspmi.r.92.4.2021 · Cited by 1
Dysrégulations de la production et de la clairance des lipoprotéines riches en triglycérides
Marmontel, O. (2018) · theses.fr (ABES) · doi:10.70675/bbd72f7dz89b7z4e60z8948z624ca506d486
Additional file 1 of ANGPTL3 impacts proteinuria and hyperlipidemia in primary nephrotic syndrome
Zhong, F., Liu, S., Li, Y., Li, G., Liu, M., Wang, J., Cui, W., Suo, Y., & Gao, X. (2022) · Figshare · doi:10.6084/m9.figshare.19579933
ANGPTL3 binds to PCSK9 to coordinately regulate intracellular lipid homeostasisPreprint
Bini, S., Pecce, V., Grimaldos, A. P., Costanzo, A. D., Minicocci, I., Covino, S., Tramontano, D., Piconese, S., D’Erasmo, L., & Arca, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.05.631413 · Cited by 1
Self-citationGrimaldos, A. P., Pacella, I., Giacomelli, T., Bini, S., Costanzo, A. D., Minicocci, I., D’Erasmo, L., Pietropaolo, G., Licursi, V., Arca, M., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07448-5
Self-citationFoss-freitas, M. C., Akıncı, B., Neidert, A., Bartlett, V. J., Hurh, E., Karwatowska‐Prokopczuk, E., & Oral, E. A. (2021) · Figshare · doi:10.6084/m9.figshare.17127352
Pedro‐Botet, J., Argüeso, R. M., Díaz, Á., Millán, J., Pascual, V., Pérez‐Martínez, P., Pintó, X., Ruiz‐García, A., & Díaz-Díaz, J. L. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2026.500961
A Nutrient-Dependent ANGPTL3–PCSK9-Containing Complex in HepG2 Cells and Human Plasma
Bini, S., Pecce, V., Grimaldos, A. P., Costanzo, A. D., Minicocci, I., Covino, S., Tramontano, D., Piconese, S., D’Erasmo, L., & Arca, M. (2026) · Biomolecules · doi:10.3390/biom16101531
“Plasma samples were obtained before and after an oral fat load [6].”
InfluentialSelf-citation
Metadata
- Authors
- Minicocci, I., Tikka, A., Poggiogalle, E., Metso, J., Montali, A., Ceci, F., Labbadia, G., Fontana, M., Di Costanzo, A., Maranghi, M., Rosano, A., Ehnholm, C., Donini, L. M., Jauhiainen, M., & Arca, M.
- Affiliations
- Sapienza University of Rome (IT)
- Finnish Institute for Health and Welfare (FI)
- Istituto per lo Sviluppo della Formazione Professionale dei Lavoratori (IT)
- Corresponding author
- Arca, Marcello
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 57
- Issue
- 6
- Pages
- 1097-1107
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4878193
- OpenAlex
- W2326075804
- Cited by
- 56
- References
- 53
- Citations by year
- 2026: 3 · 2025: 5 · 2023: 3 · 2022: 8 · 2021: 11 · 2020: 4 · 2019: 7 · 2018: 5 · 2017: 8 · 2016: 2
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1620 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- Sapienza University of Rome (Progetto Ateneo 2006, Progetto Ateneo 2011)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- ANGPTL3, postprandial lipemia, postprandial lipid metabolism, lipoprotein metabolism, triglyceride-rich lipoproteins, apolipoprotein B-48, free fatty acids, hepatic fatty acid oxidation, beta-hydroxybutyrate, high-fat meal, lipoprotein catabolism
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Fatty Acids, Nonesterified, Female, Heterozygote, Homozygote, Humans, Hypobetalipoproteinemias, Lipids, Lipoproteins, Male, Middle Aged, Mutation, Triglycerides, Postprandial Period, Angiopoietins, Apolipoprotein B-48
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.